Form 4: Vericel CFO Joseph Mara Reports RSU Vesting and Tax-Related Share Sales

Vericel Corp's Chief Financial Officer, Joseph Mara, reported the vesting of restricted stock units and subsequent tax-related share disposals on February 24, 2026.

Summary

• Joseph Anthony Mara Jr., Chief Financial Officer of Vericel Corp (VCEL), reported changes in beneficial ownership of common stock and derivative securities.
• On February 24, 2026, 4,625 shares of common stock were acquired due to the vesting of Restricted Stock Units (RSUs) granted on February 20, 2025.
• Concurrently, 1,358 shares were disposed of to satisfy tax withholding requirements related to this vesting, at a price of $38.09 per share.
• On the same date, an additional 4,625 shares of common stock were acquired from the vesting of RSUs granted on February 22, 2024.
• Another 1,358 shares were disposed of for tax withholding purposes related to this second vesting event, at a price of $38.25 per share.
• Following these transactions, Joseph Mara beneficially owns 25,904 shares of Vericel Corp common stock directly.
• Remaining Restricted Stock Units include 13,875 from the February 20, 2025 grant and 9,250 from the February 22, 2024 grant, totaling 23,125 derivative securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting standard executive compensation practices rather than a discretionary investment decision or a change in the company's operational outlook.

Positives

• The vesting of Restricted Stock Units represents a scheduled component of executive compensation, indicating continued alignment of management's interests with shareholder value through equity ownership.

Negatives

• No discretionary sales were reported; the disposals were solely for tax withholding purposes, which is a routine aspect of RSU vesting.

Future Outlook

Remaining Restricted Stock Units from the February 20, 2025 grant are scheduled to vest in annual installments on February 20, 2027, February 20, 2028, and February 20, 2029. Remaining RSUs from the February 22, 2024 grant are scheduled to vest in annual installments on February 22, 2027, and February 22, 2028.

Industry Context

StockSavvy.ai notes that the vesting of Restricted Stock Units and subsequent tax-related share disposals are standard components of executive compensation packages across the biotechnology and pharmaceutical industries. These transactions reflect a routine part of an executive's equity incentive plan rather than a discretionary investment decision.

Comparison to Industry Standards

• The structure of RSU grants with multi-year vesting schedules and tax withholding upon vesting is a common practice for executive compensation in publicly traded companies, aligning with global benchmarks for long-term incentive plans.
• This type of transaction is routine and comparable to similar equity compensation events seen at companies like Regeneron Pharmaceuticals (REGN) or Vertex Pharmaceuticals (VRTX), where executives regularly report RSU vestings and associated tax sales.

Stakeholder Impact

• Shareholders: No direct impact on company operations or strategy; reflects routine executive compensation and does not signal a change in management's confidence or company performance.

Next Steps

• Future annual installment vesting of remaining Restricted Stock Units on February 20, 2027, February 20, 2028, and February 20, 2029 (for 02/20/2025 grant).
• Future annual installment vesting of remaining Restricted Stock Units on February 22, 2027, and February 22, 2028 (for 02/22/2024 grant).

Key Dates

Recommendation

This Form 4 reports routine RSU vesting and tax-related share disposals by the CFO. These non-discretionary transactions do not indicate a change in management's outlook or the company's fundamentals, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Vericel Corp, VCEL, Form 4, Insider Transaction, RSU Vesting, Equity Compensation, Chief Financial Officer, Joseph Mara, Stock Ownership